INTRODUCTION: Assessing patient-specific risk factors for long-term mortality following resection of pancreatic adenocarcinoma can be difficult. Sarcopenia--the measurement of muscle wasting--may be a more objective and comprehensive patient-specific factor associated with long-term survival. METHODS: Total psoas area (TPA) was measured on preoperative cross-sectional imaging in 557 patients undergoing resection of pancreatic adenocarcinoma between 1996 and 2010. Sarcopenia was defined as the presence of a TPA in the lowest sex-specific quartile. The impact of sarcopenia on 90-day, 1-year, and 3-year mortality was assessed relative to other clinicopathological factors. RESULTS: Mean patient age was 65.7 years and 53.1 % was male. Mean TPA among men (611 mm²/m²) was greater than among women (454 mm²/m²). Surgery involved pancreaticoduodenectomy (86.0 %) or distal pancreatectomy (14.0 %). Mean tumor size was 3.4 cm; 49.9 % and 88.5 % of patients had vascular and perineural invasion, respectively. Margin status was R0 (59.0 %) and 77.7 % patients had lymph node metastasis. Overall 90-day mortality was 3.1 % and overall 1- and 3-year survival was 67.9 % and 35.7 %, respectively. Sarcopenia was associated with increased risk of 3-year mortality (HR = 1.68; P < 0.001). Tumor-specific factors such as poor differentiation on histology (HR = 1.75), margin status (HR = 1.66), and lymph node metastasis (HR = 2.06) were associated with risk of death at 3-years (all P < 0.001). After controlling for these factors, sarcopenia remained independently associated with an increased risk of death at 3 years (HR = 1.63; P < 0.001). CONCLUSIONS: Sarcopenia was a predictor of survival following pancreatic surgery, with sarcopenic patients having a 63 % increased risk of death at 3 years. Sarcopenia was an objective measure of patient frailty that was strongly associated with long-term outcome independent of tumor-specific factors.
INTRODUCTION: Assessing patient-specific risk factors for long-term mortality following resection of pancreatic adenocarcinoma can be difficult. Sarcopenia--the measurement of muscle wasting--may be a more objective and comprehensive patient-specific factor associated with long-term survival. METHODS: Total psoas area (TPA) was measured on preoperative cross-sectional imaging in 557 patients undergoing resection of pancreatic adenocarcinoma between 1996 and 2010. Sarcopenia was defined as the presence of a TPA in the lowest sex-specific quartile. The impact of sarcopenia on 90-day, 1-year, and 3-year mortality was assessed relative to other clinicopathological factors. RESULTS: Mean patient age was 65.7 years and 53.1 % was male. Mean TPA among men (611 mm²/m²) was greater than among women (454 mm²/m²). Surgery involved pancreaticoduodenectomy (86.0 %) or distal pancreatectomy (14.0 %). Mean tumor size was 3.4 cm; 49.9 % and 88.5 % of patients had vascular and perineural invasion, respectively. Margin status was R0 (59.0 %) and 77.7 % patients had lymph node metastasis. Overall 90-day mortality was 3.1 % and overall 1- and 3-year survival was 67.9 % and 35.7 %, respectively. Sarcopenia was associated with increased risk of 3-year mortality (HR = 1.68; P < 0.001). Tumor-specific factors such as poor differentiation on histology (HR = 1.75), margin status (HR = 1.66), and lymph node metastasis (HR = 2.06) were associated with risk of death at 3-years (all P < 0.001). After controlling for these factors, sarcopenia remained independently associated with an increased risk of death at 3 years (HR = 1.63; P < 0.001). CONCLUSIONS:Sarcopenia was a predictor of survival following pancreatic surgery, with sarcopenic patients having a 63 % increased risk of death at 3 years. Sarcopenia was an objective measure of patient frailty that was strongly associated with long-term outcome independent of tumor-specific factors.
Authors: Michael J Englesbe; Shaun P Patel; Kevin He; Raymond J Lynch; Douglas E Schaubel; Calista Harbaugh; Sven A Holcombe; Stewart C Wang; Dorry L Segev; Christopher J Sonnenday Journal: J Am Coll Surg Date: 2010-06-26 Impact factor: 6.113
Authors: Martin A Makary; Dorry L Segev; Peter J Pronovost; Dora Syin; Karen Bandeen-Roche; Purvi Patel; Ryan Takenaga; Lara Devgan; Christine G Holzmueller; Jing Tian; Linda P Fried Journal: J Am Coll Surg Date: 2010-04-28 Impact factor: 6.113
Authors: Vickie E Baracos; Tony Reiman; Marina Mourtzakis; Ioannis Gioulbasanis; Sami Antoun Journal: Am J Clin Nutr Date: 2010-02-17 Impact factor: 7.045
Authors: Sami Antoun; Laura Birdsell; Michael B Sawyer; Peter Venner; Bernard Escudier; Vickie E Baracos Journal: J Clin Oncol Date: 2010-01-19 Impact factor: 44.544
Authors: Benjamin H L Tan; Laura A Birdsell; Lisa Martin; Vickie E Baracos; Kenneth C H Fearon Journal: Clin Cancer Res Date: 2009-11-03 Impact factor: 12.531
Authors: David Blum; Aurelius Omlin; Ken Fearon; Vickie Baracos; Lukas Radbruch; Stein Kaasa; Florian Strasser Journal: Support Care Cancer Date: 2010-03 Impact factor: 3.603
Authors: Robert J S Coelen; Jimme K Wiggers; Chung Y Nio; Marc G Besselink; Olivier R C Busch; Dirk J Gouma; Thomas M van Gulik Journal: HPB (Oxford) Date: 2015-02-28 Impact factor: 3.647
Authors: Jeffery Chakedis; Gaya Spolverato; Eliza W Beal; Ingrid Woelfel; Fabio Bagante; Katiuscha Merath; Steven H Sun; Aaron Chafitz; Jason Galo; Mary Dillhoff; Jordan Cloyd; Timothy M Pawlik Journal: J Gastrointest Surg Date: 2018-05-31 Impact factor: 3.452
Authors: Motokazu Sugimoto; Michael B Farnell; David M Nagorney; Michael L Kendrick; Mark J Truty; Rory L Smoot; Suresh T Chari; Michael R Moynagh; Gloria M Petersen; Rickey E Carter; Naoki Takahashi Journal: J Gastrointest Surg Date: 2018-02-01 Impact factor: 3.452
Authors: Chris E Forsmark; Gong Tang; Hongzhi Xu; Marie Tuft; Steven J Hughes; Dhiraj Yadav Journal: Aliment Pharmacol Ther Date: 2020-04-06 Impact factor: 8.171